HCA HCA Healthcare

XNYS Up Alert

Health Care

· How we analyze

About the company

HCA Healthcare is a private hospital operator from Tennessee. Its network includes hospitals, outpatient surgery centers, urgent care clinics and other facilities, mainly in the southern US, plus some sites in the UK. As of Oct 13, 2026

Fact sheet (from the annual report) Hospitals · Nashville, USA

HCA Healthcare operates general acute care hospitals, psychiatric hospitals and rehabilitation hospitals in many states and in England. In addition, there are ambulatory surgery centers, endoscopy centers, physician practices, diagnostic centers, home health services and hospices. The acute care hospitals generally cover specialties such as internal medicine, surgery, cardiology, oncology, orthopedics and obstetrics as well as diagnostics and emergency care. The psychiatric hospitals provide inpatient, partial hospitalization and outpatient treatment. Payments come from Medicare and Medicaid, from managed care health insurers, from private insurers and directly from patients.

Automatically summarized from SEC annual report (10-K, filed Feb 10, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today −3.3%
  • 7 days −3.4%
  • 30 days +3.3%
  • 1 year −3.8%
Day range (last trading day)
−2.3%Price at 21% of the range+8.5%
52-week range
−21.3%Price at 47% of the range+23.7%
Distance from the all-time high
−19.1%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Pullback in trend · Analysis method

This method currently detects no pattern for HCA. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? In an intact uptrend (price above the 200-day line, 50-day line rising), the price pulls back to the 50-day line after a rise and closes back above it.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Fundamental analysis

HCA Healthcare · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 10, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 3 of 5 met · 3 without data

  • no data: Gross margin above 40% not stated in the SEC filings
  • no data: Operating margin above 15% not stated in the SEC filings
  • not met: Net margin above 10% 9.0%
  • no data: Return on equity above 15% negative equity
  • met: Free cash flow margin above 10% 10.2%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% −9.9%
Net margin

9.0% Fiscal year 2025

No rank: too few peers or not computed yet.

Profit after all costs, interest and taxes divided by revenue.

Return on assets

11.2% Fiscal year 2025 (total assets at year end)

No rank: too few peers or not computed yet.

Net income divided by total assets at fiscal year end.

Equity ratio

−9.9% Fiscal year 2025

No rank: too few peers or not computed yet.

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

10.2% Fiscal year 2025

No rank: too few peers or not computed yet.

Free cash flow divided by revenue.

Free cash flow

7.7B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 6 of 6 met · 1 without data

  • met: Over 3 years, revenue grew by more than 5% per year +7.9%
  • met: Over 5 years, revenue grew by more than 5% per year +8.0%
  • no data: Over 10 years, revenue grew by more than 5% per year no comparable figures over 10 years
  • met: Over 3 years, EPS grew by more than 5% per year +13.9%
  • met: Over 5 years, EPS grew by more than 5% per year +21.0%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +7.1%
Revenue growth 3 years

+7.9% per year

No rank: too few peers or not computed yet.

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+8.0% per year

No rank: too few peers or not computed yet.

Average growth per year over 5 fiscal years.

EPS growth 3 years

+13.9% per year

No rank: too few peers or not computed yet.

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+21.0% per year

No rank: too few peers or not computed yet.

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+19.0% per year

No rank: too few peers or not computed yet.

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 6 met · 1 without data

  • met: Pays a dividend 2.88 USD
  • met: Payout ratio at most 60% of earnings 10%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +46.3%
  • met: Free cash flow per share covers the dividend 11.2x
  • no data: Dividends paid over the last 5 years covered by free cash flow dividends paid or free cash flow reported for fewer than 3 years
Payout ratio

10% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+46.3% per year

No rank: too few peers or not computed yet.

Growth of the dividend per share per year.

Free cash flow coverage

11.2x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 2 of 5 met · 1 without data

  • no data: Piotroski F-Score at least 7 of 9 too many criteria without data 6 of 8 · 1 without data
  • not met: Long-term debt no higher than equity negative equity
  • not met: Current assets cover current liabilities 0.97
  • not met: Positive equity −6.0B USD
  • met: In 5 years, share count up by at most 5% −30.3%
  • met: Free cash flow positive in the last fiscal year 7.7B USD
Piotroski F-Score

6 of 8 Fiscal year 2025

No rank: not all 9 criteria have data.

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

negative equity at fiscal year end

No rank: too few peers or not computed yet.

Long-term financial debt divided by equity.

Liquidity (current ratio)

0.97 at fiscal year end

No rank: too few peers or not computed yet.

Current assets divided by current liabilities.

Change in share count

−30.3% in 5 years

No rank: too few peers or not computed yet.

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • not met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • no data: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock.

In short

  • Light green: Revenue grew over 5 years (+8.0% per year), at least as fast as the sector median.
  • Light green: Net income (total) grew over 5 years (+12.6% per year), at least as fast as the sector median; per share +21.0% per year.
  • Light yellow: Net margin 9.0%, below the sector median (12.9%).
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 41.5B USD · Net income 2.9B USD · Net margin 7.0%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 43.6B USD · Net income 2.2B USD · Net margin 5.1%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 46.7B USD · Net income 3.8B USD · Net margin 8.1%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 51.3B USD · Net income 3.5B USD · Net margin 6.8%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 51.5B USD · Net income 3.8B USD · Net margin 7.3%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 58.8B USD · Net income 7.0B USD · Net margin 11.8%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 60.2B USD · Net income 5.6B USD · Net margin 9.4%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 65.0B USD · Net income 5.2B USD · Net margin 8.1%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 70.6B USD · Net income 5.8B USD · Net margin 8.2%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 75.6B USD · Net income 6.8B USD · Net margin 9.0%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 75.6B USD · Net income 6.8B USD · Net margin 9.0%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 9.0 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue75.6B USD100.0%
Net income6.8B USD9.0%
Costs, taxes & other68.8B USD91.0%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 7.3% to 9.0%.

Net margin
  1. Fiscal year 2016: Net margin 7.0%
  2. Fiscal year 2017: Net margin 5.1%
  3. Fiscal year 2018: Net margin 8.1%
  4. Fiscal year 2019: Net margin 6.8%
  5. Fiscal year 2020: Net margin 7.3%
  6. Fiscal year 2021: Net margin 11.8%
  7. Fiscal year 2022: Net margin 9.4%
  8. Fiscal year 2023: Net margin 8.1%
  9. Fiscal year 2024: Net margin 8.2%
  10. Fiscal year 2025: Net margin 9.0%

Returns

Return on assets rose in 5 years from 7.9% to 11.2%.

Return on assets Return on equity hidden where equity is below 5% of total assets.
  1. Fiscal year 2016: Return on assets 8.6%
  2. Fiscal year 2017: Return on assets 6.1%
  3. Fiscal year 2018: Return on assets 9.7%
  4. Fiscal year 2019: Return on assets 7.8%
  5. Fiscal year 2020: Return on assets 7.9%
  6. Fiscal year 2021: Return on assets 13.7%
  7. Fiscal year 2022: Return on assets 10.8%
  8. Fiscal year 2023: Return on assets 9.3%
  9. Fiscal year 2024: Return on assets 9.7%
  10. Fiscal year 2025: Return on assets 11.2%

Equity and long-term debt

The equity ratio fell in 5 years from 1.2% to −9.9%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity −7.3B USD · Long-term debt 31.4B USD
  2. Fiscal year 2017: Equity −6.8B USD · Long-term debt 33.1B USD
  3. Fiscal year 2018: Equity −5.0B USD · Long-term debt 32.8B USD
  4. Fiscal year 2019: Equity −2.8B USD · Long-term debt 33.7B USD
  5. Fiscal year 2020: Equity 572.0M USD · Long-term debt 31.0B USD
  6. Fiscal year 2021: Equity −933.0M USD · Long-term debt 34.6B USD
  7. Fiscal year 2022: Equity −2.8B USD · Long-term debt 38.1B USD
  8. Fiscal year 2023: Equity −1.8B USD · Long-term debt 39.6B USD
  9. Fiscal year 2024: Equity −2.5B USD · Long-term debt 43.0B USD
  10. Fiscal year 2025: Equity −6.0B USD · Long-term debt 44.3B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.42 to 0.97.

Current ratio
  1. Fiscal year 2016: Current ratio 1.56
  2. Fiscal year 2017: Current ratio 1.62
  3. Fiscal year 2018: Current ratio 1.35
  4. Fiscal year 2019: Current ratio 1.44
  5. Fiscal year 2020: Current ratio 1.42
  6. Fiscal year 2021: Current ratio 1.41
  7. Fiscal year 2022: Current ratio 1.38
  8. Fiscal year 2023: Current ratio 1.18
  9. Fiscal year 2024: Current ratio 1.08
  10. Fiscal year 2025: Current ratio 0.97

Cash flow

Free cash flow rose in 5 years from 6.4B USD to 7.7B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 5.7B USD · Capital expenditure 2.8B USD · Free cash flow 2.9B USD
  2. Fiscal year 2017: Operating cash flow 5.4B USD · Capital expenditure 3.0B USD · Free cash flow 2.4B USD
  3. Fiscal year 2018: Operating cash flow 6.8B USD · Capital expenditure 3.6B USD · Free cash flow 3.2B USD
  4. Fiscal year 2019: Operating cash flow 7.6B USD · Capital expenditure 4.2B USD · Free cash flow 3.4B USD
  5. Fiscal year 2020: Operating cash flow 9.2B USD · Capital expenditure 2.8B USD · Free cash flow 6.4B USD
  6. Fiscal year 2021: Operating cash flow 9.0B USD · Capital expenditure 3.6B USD · Free cash flow 5.4B USD
  7. Fiscal year 2022: Operating cash flow 8.5B USD · Capital expenditure 4.4B USD · Free cash flow 4.1B USD
  8. Fiscal year 2023: Operating cash flow 9.4B USD · Capital expenditure 4.7B USD · Free cash flow 4.7B USD
  9. Fiscal year 2024: Operating cash flow 10.5B USD · Capital expenditure 4.9B USD · Free cash flow 5.6B USD
  10. Fiscal year 2025: Operating cash flow 12.6B USD · Capital expenditure 4.9B USD · Free cash flow 7.7B USD

Share count

The share count fell in 5 years by 30.3% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 395.9M
  2. Fiscal year 2017: Diluted share count 372.2M
  3. Fiscal year 2018: Diluted share count 355.3M
  4. Fiscal year 2019: Diluted share count 348.2M
  5. Fiscal year 2020: Diluted share count 343.6M
  6. Fiscal year 2021: Diluted share count 328.8M
  7. Fiscal year 2022: Diluted share count 294.7M
  8. Fiscal year 2023: Diluted share count 276.4M
  9. Fiscal year 2024: Diluted share count 261.8M
  10. Fiscal year 2025: Diluted share count 239.5M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.88 USD · Fiscal year 2025
Dividend growth per year
3 y +8.7%5 y –10 y –
Years without a cut
5 in a row up to now
Payout ratio
of earnings 10% of free cash flow –
Share count over 5 years
−30.3% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 0.43 USD to 2.88 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share not available
  2. Fiscal year 2017: Dividend per share not available
  3. Fiscal year 2018: Dividend per share 1.40 USD
  4. Fiscal year 2019: Dividend per share 1.60 USD
  5. Fiscal year 2020: Dividend per share 0.43 USD
  6. Fiscal year 2021: Dividend per share 1.92 USD
  7. Fiscal year 2022: Dividend per share 2.24 USD
  8. Fiscal year 2023: Dividend per share 2.40 USD
  9. Fiscal year 2024: Dividend per share 2.64 USD
  10. Fiscal year 2025: Dividend per share 2.88 USD

Payout ratios

The payout ratio rose in 5 years from 3.9% to 10.2%.

Payout ratio (earnings)
  1. Fiscal year 2016: Payout ratio (earnings) not available
  2. Fiscal year 2017: Payout ratio (earnings) not available
  3. Fiscal year 2018: Payout ratio (earnings) 13.1%
  4. Fiscal year 2019: Payout ratio (earnings) 15.9%
  5. Fiscal year 2020: Payout ratio (earnings) 3.9%
  6. Fiscal year 2021: Payout ratio (earnings) 9.1%
  7. Fiscal year 2022: Payout ratio (earnings) 11.7%
  8. Fiscal year 2023: Payout ratio (earnings) 12.7%
  9. Fiscal year 2024: Payout ratio (earnings) 12.0%
  10. Fiscal year 2025: Payout ratio (earnings) 10.2%

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+8.0% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 8.0% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+12.6% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +21.0% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 12.6% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

9.0% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 8.97 USD remained as profit – less than the median company in the sector (12.9%). Five years ago the margin was 7.3%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light gray: negative equity

– latest balance sheet

Sector Health Care: median 0.66 (40 symbols)

What does this mean? Equity is negative (e.g. due to share buybacks). A debt-to-equity ratio cannot be formed meaningfully then.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

10% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.10 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
75.6B USD
Revenue vs. prior year
+7.1%
Net income (FY)
6.8B USD
Net income vs. prior year
+17.8%
EPS (FY)
28.33 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
±0
Shares held vs. prior quarter
–
Fiscal year to Dec 31, 2025 · 10-K filed Feb 10, 2026 · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 75.6B6.8B 9.0% 28.33 2.88 10%
2024Dec 31, 2024 70.6B5.8B 8.2% 22.00 2.64 12%
2023Dec 31, 2023 65.0B5.2B 8.1% 18.97 2.40 13%
2022Dec 31, 2022 60.2B5.6B 9.4% 19.15 2.24 12%
2021Dec 31, 2021 58.8B7.0B 11.8% 21.16 1.92 9%
2020Dec 31, 2020 51.5B3.8B 7.3% 10.93 0.43 4%
2019Dec 31, 2019 51.3B3.5B 6.8% 10.07 1.60 16%
2018Dec 31, 2018 46.7B3.8B 8.1% 10.66 1.40 13%
2017Dec 31, 2017 43.6B2.2B 5.1% 5.95 – –
2016Dec 31, 2016 41.5B2.9B 7.0% 7.30 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q1/26Mar 31, 2026 19.1B1.6B 8.5% 7.15 0.78 11%
Q4/25*Dec 31, 2025 19.5B1.9B 9.6% – 0.72 –
Q3/25Sep 30, 2025 19.2B1.6B 8.6% 6.96 0.72 10%
Q2/25Jun 30, 2025 18.6B1.7B 8.9% 6.83 0.72 11%
Q1/25Mar 31, 2025 18.3B1.6B 8.8% 6.45 0.72 11%
Q4/24*Dec 31, 2024 18.3B1.4B 7.9% – 0.66 –
Q3/24Sep 30, 2024 17.5B1.3B 7.3% 4.88 0.66 14%
Q2/24Jun 30, 2024 17.5B1.5B 8.4% 5.53 0.66 12%
Q1/24Mar 31, 2024 17.3B1.6B 9.2% 5.93 0.66 11%
Q4/23*Dec 31, 2023 17.3B1.6B 9.3% – 0.60 –
Q3/23Sep 30, 2023 16.2B1.1B 6.7% 3.91 0.60 15%
Q2/23Jun 30, 2023 15.9B1.2B 7.5% 4.29 0.60 14%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $00 people $0
12 months $00 people $31.1M5 people −$31.1M

Latest transactions

  • Feb 18, 2026 McAlevey Michael R Officer Open-market sale 1,694 shares · $903.5K · SEC
  • Feb 11, 2026 Wyatt Christopher F. Officer Open-market sale 4,000 shares · $2.0M · SEC
  • Feb 11, 2026 Berres Jennifer Officer Open-market sale 4,010 shares · $2.1M · SEC
  • Feb 11, 2026 Berres Jennifer Officer Open-market sale 4,010 shares · $2.0M · SEC
  • Feb 3, 2026 Hazen Samuel N Chief executive (CEO), Director Open-market sale 120 shares · $59.7K · SEC
  • Feb 3, 2026 Hazen Samuel N Chief executive (CEO), Director Open-market sale 4,293 shares · $2.1M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +100

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+20
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)28.3
Rel. strength 60 d+9.5%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on HCA yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: HCA

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

↑ ↓ select · Enter open · Esc close